These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 13044)

  • 21. The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions.
    Ogren SO; Hall H; Köhler C; Magnusson O; Sjöstrand SE
    Psychopharmacology (Berl); 1986; 90(3):287-94. PubMed ID: 2947255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subcellular localization of dopamine-sensitive adenylate cyclase and dopamine receptor binding activities.
    Clement-Courmier Y; George R
    Life Sci; 1978 Aug; 23(6):539-43. PubMed ID: 692278
    [No Abstract]   [Full Text] [Related]  

  • 23. Effects of dopamine-like drugs on rat striatal adenyl cyclase have implications for CNS dopamine receptor topography.
    Miller R; Horn A; Iversen L; Pinder R
    Nature; 1974 Jul; 250(463):238-41. PubMed ID: 4368645
    [No Abstract]   [Full Text] [Related]  

  • 24. Three classes of dopamine receptor (D-2, D-3, D-4) identified by binding studies with 3H-apomorphine and 3H-domperidone.
    Sokoloff P; Martres MP; Schwartz JC
    Naunyn Schmiedebergs Arch Pharmacol; 1980; 315(2):89-102. PubMed ID: 7207647
    [No Abstract]   [Full Text] [Related]  

  • 25. Dopamine receptor supersensitivity and schizophrenia: a review.
    Langer DH; Brown GL; Docherty JP
    Schizophr Bull; 1981; 7(2):208-24. PubMed ID: 7025187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Narcotic dependence, narcotic action and dopamine receptors.
    Lal H
    Life Sci; 1975 Aug; 17(4):483-95. PubMed ID: 171531
    [No Abstract]   [Full Text] [Related]  

  • 27. The involvement of serotonin in the mechanism of central action of apomorphine.
    Grabowska M
    Pol J Pharmacol Pharm; 1976; 28(4):389-94. PubMed ID: 790347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug-induced growth hormone and prolactin responses in schizophrenia research.
    Lal S; Nair NP; Iskandar HI; Thavundayil JX; Etienne P; Wood PL; Guyda H
    Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):631-7. PubMed ID: 6131495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stimulation of 3H-apomorphine binding by dopamine and bromocriptine.
    Robertson HA
    Eur J Pharmacol; 1980 Jan; 61(2):209-11. PubMed ID: 7353592
    [No Abstract]   [Full Text] [Related]  

  • 30. Anti-schizophrenic drugs--membrane receptor sites of action.
    Seeman P
    Biochem Pharmacol; 1977 Oct; 26(19):1741-8. PubMed ID: 20896
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of ascorbic acid on neurochemical, behavioral, and physiological systems mediated by catecholamines.
    Tolbert LC; Thomas TN; Middaugh LD; Zemp JW
    Life Sci; 1979 Dec; 25(26):2189-95. PubMed ID: 542096
    [No Abstract]   [Full Text] [Related]  

  • 32. Functional distinction between DA-stimulated adenylate cyclase and 3H-spiperone binding sites in rat striatum.
    Waddington JL; Cross AJ; Longden A; Owen F; Poulter M
    Eur J Pharmacol; 1979 Oct; 58(3):341-2. PubMed ID: 510367
    [No Abstract]   [Full Text] [Related]  

  • 33. A comparison of in vitro and in vivo dopamine receptor antagonism produced by substituted benzamide drugs.
    Jenner P; Elliott PN; Clow A; Reavill C; Marsden CD
    J Pharm Pharmacol; 1978 Jan; 30(1):46-8. PubMed ID: 22724
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacology of [3H]apomorphine binding to bovine brain tissue.
    Arana GW; Baldessarini RJ; Harding M
    Biochem Pharmacol; 1981 Dec; 30(23):3171-9. PubMed ID: 7317102
    [No Abstract]   [Full Text] [Related]  

  • 35. Behavioral effects of apomorphine and diisobutyrylapomorphine in the mouse.
    Baldessarini RJ; Kula NS; Walton KG
    Psychopharmacology (Berl); 1977 Jun; 53(1):45-53. PubMed ID: 407613
    [No Abstract]   [Full Text] [Related]  

  • 36. Dopamine receptor sensitivity in brain and retina of rats during aging.
    Govoni S; Loddo P; Spano PF; Trabucchi M
    Brain Res; 1977 Dec; 138(3):565-70. PubMed ID: 597726
    [No Abstract]   [Full Text] [Related]  

  • 37. The effect of bromocriptine on locomotor activity and cerebral catecholamines in rodents.
    Dolphin AC; Jenner P; Sawaya MC; Marsden CD; Testa B
    J Pharm Pharmacol; 1977 Dec; 29(12):727-34. PubMed ID: 22618
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of short-term administration of valproate on serotonin-1A and dopamine receptor function in healthy human subjects.
    Delva NJ; Brooks DL; Franklin M; al-Said K; Hawken ER; Merali Z; Lawson JS; Ravindran AV
    J Psychiatry Neurosci; 2002 Nov; 27(6):429-37. PubMed ID: 12491576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolonged apomorphine-like behavioural effects of apomorphine esters.
    Borgman RJ
    Neuropharmacology; 1976 Aug; 15(8):471-8. PubMed ID: 988501
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy.
    Ettigi P; Nair NP; Lal S; Cervantes P; Guyda H
    J Neurol Neurosurg Psychiatry; 1976 Sep; 39(9):870-6. PubMed ID: 993808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.